Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Interferon-alpha, IFN-alpha lozenge, low dose IFN lozenge
Veldona · 1 trial · 3 indications
A patient with a 75% or greater decrease in total OU for three visits was considered a "sustained responder".
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | (placebo)0 IU IFNa |
| 2 | EXPERIMENTAL | (Veldona)500 IU IFNα bid |
| 3 | EXPERIMENTAL | (Veldona)1000 IU IFNα bid |
| Name | Type | Description |
|---|---|---|
| Veldona, | BIOLOGICAL | Very low dose oral natural human interferon alpha lozenges |
Inclusion Criteria: * Is a male or a non-pregnant, non-lactating female. * Has a history and clinical presentation consistent with a diagnosis of Behçet's Disease and meets International Study Group criteria (Appendix B). * Has a history of oral ulcers for at least 12 months. * Has a history of mon...
Veldona is being developed for Behcet syndrome, a condition that involves mucocutaneous ulceration, including oral ulcers. It is an immunology asset studied in adults 18 years and older. The clinical program has focused on low dose interferon alpha treatment for the oral ulcers associated with Behcet's disease.
Veldona is developed by Ainos, Inc., which trades under the ticker AIMD. The company is the sponsor of the clinical program for the asset in Behcet syndrome.
Veldona is in Phase 2 development. It is investigational and has not been approved by the FDA. One Phase 2 trial has been completed, and no trials are currently active.
Veldona has been studied in one completed Phase 2 trial, NCT00483184, titled Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease. The trial enrolled 84 participants in Turkey, was randomized, double blind, and placebo controlled, and included adults 18 years and older of all sexes.